Lurasidone: An Atypical Antipsychotic for Schizophrenia

Risbood, Vineeta; Lee, Jennifer R; Roche-Desilets, Jennifer; Fuller, Matthew

doi:10.1345/aph.1m721

Cited by 18 publications

(16 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The T1/2 was found somewhat different in patients with schizophrenia (range 28.8 --37.4 h) after a single dose (120 --160 mg/day) from healthy volunteers (range 12.2 --18.3 h) and after a single-dose administration of 100 mg or less [13].…”

Section: Pharmacokinetics/pharmacodynamics Proprieties Of Lurasidonementioning

confidence: 79%

“…It was indicated as causal of a reduction of neurotrophin expression in the pre-frontal cortex of psychotic states, but lurasidone chronic high dosage treatment normalizes this reduction [61]. Such evidence suggests that epigenetic-related mechanisms may have a relevant role in the long-term activity of anti-psychotic actions of lurasidone [13].…”

Section: Development Of Clinical Studies On Lurasidonementioning

confidence: 99%

“…Unlike other antipsychotic agents, neurocognitive tests suggest that lurasidone can restore the memory consolidation process disrupted by specific agents such as MK-801 and may be clinically useful for treatment of cognitive deficits in schizophrenia [13]. For example, this has been shown in animals in passive avoidance tests for memory consolidation; in the Morris water maze test for reference memory; in the radial-arm maze test for working memory; in the object recognition test for working memory depending on the functional integrity of regions such as the prefrontal cortex and hippocampus; in novel object recognition that measures executive functions depending on the intact functions of the prefrontal cortex [13].…”

Section: Development Of Clinical Studies On Lurasidonementioning

confidence: 99%

See 2 more Smart Citations

Potential use of lurasidone for the treatment of bipolar psychosis

Carta

Moro

Nardi

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

The pharmacological profile of lurasidone, its action on receptors, its role in neurogenesis and its cognitive performance suggests a potential use in psychotic episodes of BDs and mania. This hypothesis is also supported by the clinical observations from case reports concerning resolutions of BPID with psychotic features, where psychotic episodes were diagnosed as schizophrenia and reclassified as BDs after the patient was able to reconstruct his/her clinical history. The use of lurasidone may have the advantage of a low side-effect profile and a possible efficacy in preventing the impairment of cognitive performance. However, randomized clinical trials assessing the efficacy of lurasidone in the treatment of manic episodes as well as manic episodes with psychotic components are still needed.

show abstract

Section: Pharmacokinetics/pharmacodynamics Proprieties Of Lurasidonementioning

confidence: 79%

Section: Development Of Clinical Studies On Lurasidonementioning

confidence: 99%

Section: Development Of Clinical Studies On Lurasidonementioning

confidence: 99%

See 1 more Smart Citation

Potential use of lurasidone for the treatment of bipolar psychosis

Carta

Moro

Nardi

et al. 2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

“…Lurasidone also has partial agonistic properties of high affinity at the 5-HT 1A receptor 24. Lurasidone has much greater binding affinity at the 5-HT 7 receptor compared to other second-generation antipsychotics, and the blockade of this receptor subtype is also thought to contribute to lurasidone’s antipsychotic actions 24,26. There have also been several studies that suggested the positive impacts of 5-HT 7 antagonistic effects on memory27 and affective symptoms 28.…”

Section: Review Of the Pharmacology Mode Of Action And Pharmacokinementioning

confidence: 99%

“…They also have high binding affinity at 5-HA 1A and 5-HT 7 , which is comparable to lurasidone. Both metabolites, especially ID-14283, seem to contribute to the antipsychotic action of lurasidone 24,26. The T max of ID-14283 is 1.6 hours to 1.8 hours, and its half-life (T 1/2 ) is 7.48–10 hours 26,31…”

Section: Review Of the Pharmacology Mode Of Action And Pharmacokinementioning

confidence: 99%

Lurasidone as a potential therapy for bipolar disorder

Woo

Wang²,

Bahk³

2013

NDT

View full text Add to dashboard Cite

Lurasidone is a benzisothiazol derivative and an atypical antipsychotic approved by the US Food and Drug Administration for the acute treatment of adults with schizophrenia (October 2010) and bipolar 1 depression (June 2013). Lurasidone has a strong antagonistic property at the D2, serotonin (5-HT)2A, and 5-HT7 receptors, and partial agonistic property at the 5-HT1A receptor. Lurasidone also has lower binding affinity for the α2C and 5-HT2C receptor. Lurasidone is rapidly absorbed (time to maximum plasma concentration: 1–3 hours), metabolized mainly by CYP3A4 and eliminated by hepatic metabolism. In two large, well-designed, 6-week trials in adult patients with bipolar 1 depression, lurasidone monotherapy and adjunctive therapy with mood stabilizers were significantly more effective than placebo at improving depressive symptoms assessed using the Montgomery–Åsberg Depression Rating Scale total score. In both trials, lurasidone also reduced the Clinical Global Impression–Bipolar Severity depression score to a greater extent than placebo. In these two trials, discontinuation rates due to adverse events in the lurasidone group were small (<7%) and were not different from those of the placebo group. The most common adverse events in the lurasidone group were headache, nausea, somnolence, and akathisia. The changes in lipid profiles, weight, and parameters of glycemic control were minimal, and these findings were in line with those observed in schizophrenia trials. Further active comparator trials and long-term tolerability and safety data in bipolar patients are required. Lurasidone may be an option for the management of depressive symptoms in patients with bipolar 1 disorder, and it may be considered as a treatment alternative for patients who are at high risk for metabolic abnormalities.

show abstract